Your session is about to expire
← Back to Search
Upadacitinib for Pediatric Eczema
Study Summary
This trial looks at the safety, how the body processes, and side effects of a medication given to children with severe eczema. The study also looks at how palatable the medication is to children.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I weigh more than 10kg and am at least 3 years old.I have been diagnosed with atopic dermatitis according to specific criteria.I have been diagnosed with atopic dermatitis for over 6 months.I've had a bad reaction or no improvement from specific skin treatments in the last year.I have been diagnosed with atopic dermatitis for over 6 months.I have been treated with a JAK inhibitor before.I have been diagnosed with atopic dermatitis according to Hanifin and Rajka's criteria.I have severe eczema as diagnosed by a doctor.I haven't taken strong medication that affects drug metabolism in the last 30 days.
- Group 1: Part 1; Cohort 4
- Group 2: Part 2
- Group 3: Part 1; Cohort 1
- Group 4: Part 1; Cohort 2
- Group 5: Part 1; Cohort 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you elucidate on the other scientific investigations related to Upadacitinib (ABT-494)?
"First investigated in 2015, Upadacitinib (ABT-494) has since been studied extensively. A total of 21 trials have already been completed, with an additional 21 currently enrolling participants at various medical centres - the largest concentration being in Salt Lake City, Utah."
How many locations are involved in conducting this trial?
"Presently, 15 different sites are accepting participants for this trial. Salt Lake City, Coral Gables and Arlington are among the many locations that one can register at to participate in this study. To reduce any travelling needs, it is recommended to choose a site closest to your area of residence should you decide to take part."
What is the maximum number of participants accepted to this trial?
"At this moment in time, recruitment for the clinical trial is closed. The study was initially posted on January 31st 2019 and last updated August 1st 2022. If you are seeking alternative trials, 235 different studies involving eczema in infants require participants as do 21 studies which utilize Upadacitinib (ABT-494)."
What primary illnesses is Upadacitinib (ABT-494) utilized to address?
"Patients suffering from systemic conditions such as rheumatoid arthritis that cannot be treated using methotrexate may benefit from Upadacitinib (ABT-494) therapy."
Is this the earliest iteration of research into this topic?
"Currently, there are 21 ongoing studies concerning the drug Upadacitinib (ABT-494) taking place in 54 different countries and 953 cities. The first clinical trial of this medication was launched by AbbVie back in 2015 and involved 1629 patients who completed Phase 3 trials successfully. Since then, an additional 21 research projects have been accomplished."
Has Upadacitinib (ABT-494) received the necessary regulatory clearance from the FDA?
"As this is a Phase 1 trial, meaning there exists little data verifying efficacy and safety for Upadacitinib (ABT-494), our team assessed it to be at the lower end of risk, with a score of 1."
Is the age restriction for this trial limited to those over 25 years of age?
"The age requirements for this research are between 2 years and 12 years. In total, there is a range of 108 clinical trials available to minors and 184 studies targeting the elderly population."
Are there any eligibility requirements to join this clinical trial?
"This medical trial currently needs 32 participants aged between 2 and 12 years old who suffer from infantile eczema. Other criteria for enrolment include a minimum body weight of 10 kilograms at the baseline visit, confirmation that their symptoms meet Hanifin & Rajka's definition of Atopic dermatitis (AD), active severe AD as indicated by Eczema Area Severity Index (EASI) scores, Investigator Global Assessment (IGA) readings, and Body Surface Area (BSA). Lastly, it is necessary to have documented evidence that topical corticosteroids or calcineurin inhibitors are either ineffective or medically inad"
Is enrollment for this medical experiment still open?
"According to clinicaltrials.gov, this trial has closed recruitment since August 1st 2022 and is no longer actively seeking participants. Initially posted on January 31st 2019, 256 other studies are available for potential enrolment at present."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger